Understanding the tumor microenvironment for effective immunotherapy

Cited by (342)

Items 101–200 of 342

1. mRNA-based personalized cancer vaccines: opportunities, challenges and outcomes
   Arina A. Ibragimova, A. A. Fedorov, Kirill M. Kirilenko, Е. Л. Чойнзонов, Evgeny V. Denisov, Marina R. Patysheva · 2025 · Acta Naturae
2. Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics
   Ritu Ritu, Prakash Chandra, Asmita Das · 2023 · Clinical and Experimental Medicine
3. The Role of Estrogen and Estrogen Receptors in Head and Neck Tumors
   Jacqueline-Katrin Kranjčević, Josipa Čonkaš, Petar Ozretić · 2024 · Cancers
4. Prognostic value of systemic inflammation response index in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysis
   Xiaobin Gu, Xiaodan Han, Yanli Shen, Yonggang Shi · 2024 · Annals of Medicine
5. Liposomes as immunotherapeutic carriers: A game-changer in cancer therapy
   Sepehr Hoseinzadeh Moghaddam, Abulfazl Vatankhah, Fatemeh Oroojalian, Prashant Kesharwani, Amirhossein Sahebkar · 2025 · Journal of Drug Delivery Science and Technology
6. B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
   Jhe‐Cyuan Guo, Chia‐Lang Hsu, Yenlin Huang, Chia‐Chi Lin, Ta‐Chen Huang, I‐Chen Wu, Chen‐Yuan Lin, Ming‐Yu Lien, Hung‐Yang Kuo, Ann‐Lii Cheng et al. · 2022 · Frontiers in Oncology
7. Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations
   Rafia Ali, Huimin Shao, Pegah Varamini · 2022 · Pharmaceutics
8. Neutrophil elastase as a potential biomarker related to the prognosis of gastric cancer and immune cell infiltration in the tumor immune microenvironment
   Wangqiang Jia, Qianwen Luo, Jiang Wu, Yuanchao Shi, Quanlin Guan · 2023 · Scientific Reports
9. Associations between HIFs and tumor immune checkpoints: mechanism and therapy
   Liu, Jiayu, Jiang, Ying, Chen, Lingyan, Qian, Zhiwen, Zhang, Yan · 2024 · Discover Oncology
10. METTL14 regulates CD8+T-cell activation and immune responses to anti‐PD‐1 therapy in lung cancer
    Chongqi Sun, Jian Wang, Huixing Li, Luyao Liu, Yu Lin, Ling Zhang, Xianglong Zu, Yizhi Zhu, Yongqian Shu, Dong Shen et al. · 2024 · World Journal of Surgical Oncology
11. Prognostic value of tumor-infiltrating lymphocyte subtypes and microorganisms in triple-negative breast cancer
    Yating Shi, Zhi Guo, Qiang Wang, Huan Deng · 2024 · Journal of Cancer Research and Therapeutics
12. Aberrantly Expressed MicroRNAs in Cancer-Associated Fibroblasts and Their Target Oncogenic Signatures in Hepatocellular Carcinoma
    Jung Woo Eun, Hye Ri Ahn, Geum Ok Baek, Moon Gyeong Yoon, Ju A Son, Ji Hyang Weon, Jung Hwan Yoon, Hyung Seok Kim, Ji Eun Han, Soon Sun Kim et al. · 2023 · International Journal of Molecular Sciences
13. High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer
    Shuning Xu, Danyang Li, Tao Ning, Yao Lu, Yansha Sun, Hua Bai, Lei Qiao, Ting Deng, Ying Liu · 2025 · Frontiers in Immunology
14. Functionalized hyaluronic acid biomaterials-encouraged cancer immunotherapy through CD44-mediated targeting and cell surface engineering: A review
    Ashok Kumar Jangid, Kyung Mu Noh, Chae Eun Lee, Hee Won Park, Jaewon Park, Sungjun Kim, Kyobum Kim · 2025 · International Journal of Biological Macromolecules
15. Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas
    Habib Sadeghirad, James H. Monkman, Ahmed Murtaza Mehdi, Rahul Ladwa, Kenneth John O'Byrne, Brett G.M. Hughes, Arutha Kulasinghe · 2022 · Frontiers in Immunology
16. Therapeutic resurgence of 6-diazo-5-oxo-l-norleucine (DON) through tissue-targeted prodrugs
    Kateřina Novotná, Lukáš Tenora, Barbara Stauch Slusher, Rana Rais · 2024 · Advances in pharmacology
17. Breast cancer immunotherapy: Realities and advances
    Aixa Medina, Jeismar Carballo, Eglys B. González-Marcano, Isaac Blanca, Ana Federica Convit · 2024 · Cancer Innovation
18. Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment
    Mohammad Saleem, Abigail E. Watson, Aisha Anwaar, Ahmed Omar Jasser, Nabiha Yusuf · 2025 · Biomolecules
19. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
    Qian Chen, Xiaoling Shang, Geoffrey Liu, Xinchun Ma, Wenfei Han, Xiuwen Wang, Yanguo Liu · 2022 · Frontiers in Immunology
20. A predictive radiotranscriptomics model based on DCE-MRI for tumor immune landscape and immunotherapy in cholangiocarcinoma
    Lu Chen, Guotao Yin, Ziyang Wang, Zifan Liu, Chunxiao Sui, Kun Chen, Tianqiang Song, Wengui Xu, Lisha Qi, Xiaofeng Li · 2024 · BioScience Trends
21. Contemporary Approaches to Immunotherapy of Solid Tumors
    A. V. Kuznetsova, Ksenia А. Glukhova, О. П. Попова, Белецкий Игорь Петрович, Ivanov Aa · 2024 · Cancers
22. Folic acid-targeted redox responsive polylactic acid-based nanoparticles co-delivering pirarubicin and salinomycin suppress breast cancer tumor growth in vivo
    Priya Gupta, Ankushi Bansal, Harshdeep Kaur, Mohd Anees, Neetu Singh, Harpal Singh · 2024 · Nanoscale
23. Immune checkpoints in rheumatoid arthritis: progress and promise
    Annabelle Small, Katie Lowe, Mihir D. Wechalekar · 2023 · Frontiers in Immunology
24. Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review
    Yanna Lei, Sha Zhao, Ming Jiang · 2021 · Frontiers in Immunology
25. Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions
    Mahalakshmi Devaraji, Binoy Varghese Cheriyan · 2025 · Journal of the Egyptian National Cancer Institute
26. Beta-Adrenergic Blockade in Advanced Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Multicentric Study
    Ana Duarte Mendes, Ana Rita Freitas, Rodrigo Santos Vicente, Ricardo Ferreira, Telma Martins, Maria João Ramos, Carlota Baptista, Bruno Miguel Silva, Inês Margarido, Marina Miguel Vitorino et al. · 2024 · Cureus
27. Immune Cytolytic Activity and Strategies for Therapeutic Treatment
    Stephanie Agioti, Apostolos Zaravinos · 2024 · International Journal of Molecular Sciences
28. Mechanism and design of organic afterglow luminescent probes for cancer theranostics
    Zhiyuan Gao, Yifei Zhang, Qian Liu, Dan Ding · 2024 · MedMat.
29. Immune Checkpoint Inhibitor-Induced Pancreatic Injury (ICI-PI) in Adult Cancer Patients: A Systematic Review and Meta-Analysis
    Cha Len Lee, Israt Jahan Riya, Ifrat Jahan Piya, Thiago Pimentel Muniz, Marcus Otho Butler, Samuel David Saibil · 2025 · Cancers
30. Transcriptomic analysis identifies CYP27A1 as a diagnostic marker for the prognosis and immunity in lung adenocarcinoma
    Yi Yin, Muqun He, Yunjian Huang, Xianhe Xie · 2023 · BMC Immunology
31. Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival
    Vahid Yaghoubi Naei, James H. Monkman, Habib Sadeghirad, Ahmed Murtaza Mehdi, Tony Blick, William J. Mullally, Kenneth John O'Byrne, Majid Ebrahimi Warkiani, Arutha Kulasinghe · 2024 · Clinical & Translational Immunology
32. Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltration
    Dechao Cai, Xiao Ma, Huihui Guo, Haotian Zhang, Ashuai Bian, Haoran Yu, Wendan Cheng · 2022 · Journal of Orthopaedic Surgery and Research
33. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma
    Wenqian Zhi, Ye Wang, Chenyu Jiang, Yuqin Gong, Qiuyan Chen, Xiang Mao, Wensheng Deng, Shasha Zhao · 2023 · Frontiers in Immunology
34. In situ characterization of the tumor microenvironment
    Habib Sadeghirad, Vahid Yaghoubi Naei, Kenneth John O'Byrne, Majid Ebrahimi Warkiani, Arutha Kulasinghe · 2024 · Current Opinion in Biotechnology
35. Prospect of bacteria for tumor diagnosis and treatment
    Yuyao Xu, Chenhao Zhao, Xin Ma, Haifang Zhang · 2022 · Life Sciences
36. Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer
    Xiaocong Ma, Weimin Fang, Duo Wang, Ni Shao, Jifeng Chen, Tianqi Nie, Cuiqing Huang, Yanyu Huang, Liangping Luo, Zeyu Xiao · 2023 · Pharmaceutics
37. Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer
    Shiyan Yan, Jian‐Gao Fan · 2024 · World Journal of Gastroenterology
38. The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
    Nathan J. Dean, Paolo D. d’Arienzo, Hajir Ibraheim, Karla A. Lee, Anna Claire Olsson-Brown, David James Pinato, Nick Powell · 2024 · Best Practice & Research Clinical Gastroenterology
39. Targeting the Adenosine A2A Receptor as a Novel Therapeutic Approach for Renal Cell Carcinoma: Mechanisms and Clinical Trial Review
    Ting‐Yu Chen, Ya-Chuan Chang, Chia‐Ying Yu, Wen‐Wei Sung · 2024 · Pharmaceutics
40. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
    Yoichiro Narikawa, Atsuo Kuramasu, Masahiro Hosonuma, Masakazu Murayama, Eiji Funayama, Akiko Sasaki, Yuta Baba, Hitoshi Toyoda, Junya Isobe, Kohei Tajima et al. · 2025 · Cancer Immunology Immunotherapy
41. Colorectal cancer organoids drive hypoxia, TGF-β, and patient-specific diversification of NK cell activation programs
    Andreas von Kries, Irene Garcés-Lázaro, Bianca M Balzasch, Carsten Sticht, Indra A. Shaltiël, Kim E. Boonekamp, Annika Sams, Alessia Triassi, Tomáš Hofman, Elke Burgermeister et al. · 2025 · Journal for ImmunoTherapy of Cancer
42. The emerging roles and mechanism of N6-methyladenosine (m6A) modifications in urologic tumours progression
    Wenhao Zhu, Renshan Zhao, Xiaomin Guan, Xu Wang · 2023 · Frontiers in Pharmacology
43. Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing
    Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Véronique Lullier, Richard Béliveau, Christian Marsolais, Borhane Annabi · 2024 · Frontiers in Immunology
44. Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip
    Pooja Suryavanshi, Dhananjay Bodas · 2024 · Nanotheranostics
45. Nanoengineered drug delivery in cancer immunotherapy for overcoming immunosuppressive tumor microenvironment
    Sei Hyun Park, Ryounho Eun, Janghun Heo, Yong Taik Lim · 2022 · Drug Delivery and Translational Research
46. From the Catastrophic Objective Irreproducibility of Cancer Research and Unavoidable Failures of Molecular Targeted Therapies to the Sparkling Hope of Supramolecular Targeted Strategies
    И. В. Алексеенко, Liya G. Kondratyeva, И. П. Чернов, Eugene D. Sverdlov · 2023 · International Journal of Molecular Sciences
47. A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases
    Jianpeng Li, Jinlong Cao, Pan Li, Ran Deng, Zhiqiang Yao, Lijun Ying, Junqiang Tian · 2022 · International Journal of General Medicine
48. The Association Between Albumin Levels and Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
    Deniz Can Güven, Taha Koray Şahin, Enes Erul, Alessandro Rizzo, Angela Dalia Ricci, Şuayib Yalçın · 2022 · Research Square
49. Designing a multi-epitope vaccine targeting UPF0721 of meningitis-causing Salmonella enterica serovar Typhimurium strain L-4126 by utilizing immuno-informatics and in silico approaches
    Elham Mohammed Khatrawi, Syed Luqman Ali, Syed Yasir Ali, Aigul Abduldayeva, Alaa S. Alhegaili · 2025 · Molecular Systems Design & Engineering
50. Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Yongfa Lei, Xiao‐Tian Liang, Hua Zhu, Jin Wang, Xiaochen Zhang, Siliang Duan, Weiming Liang · 2025 · Frontiers in Immunology
51. Non-Coding RNAs Implicated in the Tumor Microenvironment of Colorectal Cancer: Roles, Mechanisms and Clinical Study
    Zhaoxu Wu, Qiang Ju · 2022 · Frontiers in Oncology
52. Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
    Nancy Alnassar, Jonathan M.J. Derry, Giuseppe Luigi Banna, Dariusz C. Górecki · 2024 · Translational Lung Cancer Research
53. Precise In Situ Delivery of a Photo-Enhanceable Inflammasome-Activating Nanovaccine Activates Anticancer Immunity
    Yang Zhou, Li Pang, Tao Ding, Kang Chen, Jinzhao Liu, Meicen Wu, Weiping Wang, Kwan Man · 2024 · Cancer Research
54. Statistical Analysis of Quantitative Cancer Imaging Data
    Shariq Mohammed, Maria Masotti, Nathaniel Osher, Satwik Acharyya, Veerabhadran Baladandayuthapani · 2024 · Statistics and data science in imaging.
55. Development and validation of prognostic models for colon adenocarcinoma based on combined immune-and metabolism-related genes
    Huizhong Jiang, Bing Yang, Yali Jiang, Xun Liu, Da-lin Chen, Feng-Xi Long, Yang Zhu, Dongxin Tang · 2022 · Frontiers in Oncology
56. A pan-cancer analysis of homeobox family: expression characteristics and latent significance in prognosis and immune microenvironment
    Yuanhui Wang, Jie Gao, Ziyi Ren, Ziyi Shen, Wei Gu, Qinyi Miao, Xiaomeng Hu, Yan Ping Wu, Wei Liu, Jia Jia et al. · 2025 · Frontiers in Oncology
57. Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer
    Janna Berg, Ann Rita Halvorsen, May‐Bente Bengtson, Morten Lindberg, Bente Lise Halvorsen, Pål Aukrust, Åslaug Helland, Thor Ueland · 2022 · Frontiers in Immunology
58. Immune activity score to assess the prognosis, immunotherapy and chemotherapy response in gastric cancer and experimental validation
    Xuan Wu, Fengrui Zhou, Boran Cheng, Gangling Tong, Minhua Chen, Lirui He, Li Zhu, Shaokang Yu, Shubin Wang, Liping Lin · 2023 · PeerJ
59. Leveraging spatial omics for the development of precision sarcoma treatments
    Cui Tu, Arutha Kulasinghe, Andrew P. Barbour, Fernando Souza-Fonseca-Guimarães · 2024 · Trends in Pharmacological Sciences
60. Single-cell RNA-sequencing reveals cellular heterogeneity and immune microenvironment characteristics between ocular adnexal mucosa-associated lymphoid lymphoma and IgG4−related ophthalmic disease
    Yu Yang, Yujiao Wang, Xuelian Jin, Weimin He · 2025 · Frontiers in Immunology
61. Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review)
    Xiaohong Lyu, Jiashu Han, Lin Chen, Yidong Zhou, Weibin Wang · 2025 · International Journal of Oncology
62. Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model
    Sung‐yoon Yang, Jin-Mu Yi, Jaemoo Chun, Seong-Won Park, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Mi-Kyung Jeong · 2023 · Frontiers in Pharmacology
63. Comprehensive analysis on clinical significance and therapeutic targets of LDL receptor related protein 11 (LRP11) in liver hepatocellular carcinoma
    Wonbeak Yoo, Ae‐Kyeong Kim, Hae Un Kook, Kyunghee Noh · 2024 · Frontiers in Pharmacology
64. Exosome‐related lncRNA score: A value‐based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma
    Zhan Yang, Xiaoting Zhang, Ning Zhan, Lining Lin, Jingyu Zhang, Lianjie Peng, Tao Qiu, Yaxian Luo, Chundi Liu, Chaoran Pan et al. · 2024 · Cancer Medicine
65. Identifying immune subtypes of uterine corpus endometrial carcinoma and a four-paired-lncRNA signature with immune-related lncRNAs
    Nan Li, Kai Yu, Lin Zhong, Dingyuan Zeng · 2021 · Experimental Biology and Medicine
66. Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy
    Katie Maurer, Cameron Y. Park, Shouvik Mani, Mehdi Borji, Livius Penter, Yinuo Jin, Jia Yi Zhang, Crystal S. Shin, James R. Brenner, Jackson Southard et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
67. Exploring CISD1 as a multifaceted biomarker in cancer: Implications for diagnosis, prognosis, and immunotherapeutic response
    Caiyue Li, Zhipin Liang, Gabrielle Vontz, Connor Kent, Wenbo Ma, Lei Liu, Riya Dahal, Jovanny Zabaleta, Guoshuai Cai, Jia Zhou et al. · 2025 · Genes & Diseases
68. Immune checkpoint inhibitor-related thrombocytopenia: Current status and future perspectives
    Peng-Fei Zhang, Xiao-Cui Ye, Xuan-Qiong Shi, Ling-Xuan Fu, Zhi-Han Yang · 2025 · Critical Reviews in Oncology/Hematology
69. Lactic Acid in Tumour Biology
    Cristina Cruz, Ignasi Barba · 2026 · Metabolites
70. Unraveling the potential of targeting methionine metabolism in cancer
    Bang-Qi Wang, Xu-Chu Li, Zhenyu Huo, Kai Zeng, Shen Chen, Yuning Wang, Yiming Zhu, Yuyang Huang, Jiatong Ding, Yuanting Cai et al. · 2026 · Cancer Letters
71. Defining the tumor microenvironment of non‐small cell lung cancer
    Kidane Siele Embaye, Tony Blick, Vahid Yaghoubi Naei, Kenneth John O'Byrne, Brett G.M. Hughes, Arutha Kulasinghe · 2026 · Immunology and Cell Biology
72. Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies
    İzzet Altun, Yusuf Mert Demirlenk, Dila Atar, Enes Çevik, Seyda Gulenay Gunduz, Hassan Albadawi, Rahmi Öklü · 2024 · Journal of Vascular and Interventional Radiology
73. Sphingosine 1-phosphate derived from tumor-educated hepatic stellate cells combining with S1PR4 promotes tumor associated macrophages differentiation through FAO modulation
    Rui Feng, Zilin Cui, Long Yang, Zirong Liu · 2025 · Scientific Reports
74. Increased Apolipoprotein A1 Expression Correlates with Tumor-Associated Neutrophils and T Lymphocytes in Upper Tract Urothelial Carcinoma
    Chih‐Chia Chang, Chia-Bin Chang, Chiung-Ju Chen, Chun‐Liang Tung, Chi‐Feng Hung, Wei‐Hong Lai, Cheng‐Huang Shen, Chang‐Yu Tsai, Ya-Yan Lai, Ming‐Yang Lee et al. · 2024 · Current Issues in Molecular Biology
75. Immune Evasion in Cancer Is Regulated by Tumor-Asociated Macrophages (TAMs): Targeting TAMs
    Megan Jung, Benjamin Bonavida · 2024 · Critical Reviews™ in Oncogenesis
76. Single-cell data revealed exhaustion of characteristic NK cell subpopulations and T cell subpopulations in hepatocellular carcinoma
    Zhong-Ning Cui, Hong-Zhi Li, Chunli Liu, Juan Wang, Chunguang Chen, Shanlei Hu, Xiaoli Zhao, Guang-Ming Li · 2024 · Aging
77. Essential m6A Methylation Regulator HNRNPC Serves as a Targetable Biomarker for Papillary Renal Cell Carcinoma
    Jiajin Wu, Yuang Wei, Chenkui Miao, Songbo Wang, Xiaoyi Wang, Zengjun Wang · 2022 · Journal of Oncology
78. Comparative study of the genomic landscape and tumor microenvironment among large cell carcinoma of the lung, large cell neuroendocrine of the lung, and small cell lung cancer
    Fanghua Li, Yue Yang, Ying Xu, Ke Li, Linhong Song, Xue Yang, Dandan Dong · 2023 · Medicine
79. Prognostic signature and immune landscape of 5-methylcytosine-related long non-coding RNAs in gastric cancer
    Qingyu Song, Jingyu Wu, Hao Wan, Desen Fan · 2024 · Heliyon
80. Comprehensive pan-cancer analysis of HSPG2 as a marker for prognosis
    Fangjun Chen, Xing Gu, Guangliang Qiang · 2025 · BMC Medical Genomics
81. Emerging Techniques of Translational Research in Immuno-Oncology: A Focus on Non-Small Cell Lung Cancer
    Mora Guardamagna, Eduardo Zamorano, Víctor Albarrán-Artahona, Andres Mesas, José Carlos Benítez · 2025 · Cancers
82. IL12-based phototherapeutic nanoparticles through remodeling tumor-associated macrophages combined with immunogenic tumor cell death for synergistic cancer immunotherapy
    Jinyang Zhang, Wenyue Gao, Guilei Ma · 2025 · Biomaterials Science
83. Ferritin Nanocomplex-Empowered “Three Birds with One Stone” Strategy for Cancer Immunotherapy
    Wenyue Gao, Xinyue Yang, Tianshu Miao, Yuchen Qi, Guilei Ma · 2025 · ACS Applied Materials & Interfaces
84. Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance
    Maliheh Hasannia, Mahdi Abounoori, Fatemeh Mahmoudian, Maryam Shirzad, Abbas Rahdar, Selamu Duguna, Sadanand Pandey · 2026 · Frontiers in Oncology
85. Integrated Analysis of C16orf54 as a Potential Prognostic, Diagnostic, and Immune Marker across Pan-Cancer
    Xinna Du, Wei Xia, Weiping Fan, Xuan Shen, Hongyan Wu, Hu Zhang · 2022 · Disease Markers
86. Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification
    Zehao Chen, Dongnian Du, Jiajuan Li, Wenming Zhang, Jianghua Shao · 2024 · Translational Cancer Research
87. Cancer-associated Fibroblasts (CAFs) Regulate Lung Cancer Malignant Progression by Transferring SERPINE2 (PN1) via Exosomes
    Yu Chen, Sihong Zhu, Ling Yang, Yu‐Fen Lu, Xiaoqun Ye · 2024 · Current Molecular Medicine
88. New onset of hypertension associated with immune checkpoint inhibitor therapy in cancer patients
    HangYu Watson, Nolan Holley, Tabot Ntoung Nkongho, Brijesh D. Patel · 2025 · Immunotherapy
89. Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment
    Priyanka Singh, Monika Yadav, Karishma Niveria, Anita Kamra Verma · 2022 · Exploration of Medicine
90. Sialic acid-functionalized nanomaterials for targeted cancer therapy, diagnosis, and theranostics
    Abulfazl Vatankhah, Sepehr Hoseinzadeh Moghaddam, Fatemeh Oroojalian, Prashant Kesharwani, Amirhossein Sahebkar · 2025 · International Journal of Pharmaceutics
91. Vitamin‐Engineered Nanoplatforms in Precision Oncology: Integrating Immunotherapy, Delivery Systems, and Theranostics
    Ruowa Xu, Yunlong Gao, Hailong Zhang, Zichao Luo · 2025 · MedComm – Biomaterials and Applications
92. scSurv: a deep generative model for single-cell survival analysis
    Chikara Mizukoshi, Yasuhiro Kojima, Shuto Hayashi, Ko Abe, Daisuke Kasugai, Teppei Shimamura · 2025 · Bioinformatics
93. High-throughput engineered tumor organoids reveal ROCK signaling as an immunotherapeutic target in triple-negative breast cancer
    Xiaolong Zhou, Yu Zhu, George Michael Nicolas, Fulin Zhou, Davit Khutsishvili, Wanlong Wang, Zhuoyao Song, Wenxin Xu, Yu Ye, Yu Zhang et al. · 2026 · Cell Reports
94. NGS-based Tissue-Blood TMB Comparison and Blood-TMB Monitoring in Stage-III Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
    Luxi Ye, Xiao Chu, Jianjiao Ni, Li Chu, Xi Yang, Zhengfei Zhu · 2024 · Cancer Investigation
95. Pan-Cancer Analysis and Experimental Validation of CEND1 as a Prognostic and Immune Infiltration-Associated Biomarker for Gliomas
    Jinyang Ma, Bojuan Lang, Lei Wang, Youdong Zhou, Changtao Fu, Chunlei Tian, Lixin Xue · 2024 · Molecular Biotechnology
96. Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives
    Elinor R. Gatfield, John A. Tadross, Will Ince · 2024 · Future Oncology
97. Prognostic and immune infiltration implications of SIGLEC9 in SKCM
    Yang Peipei, Yunhui Jiang, Rong Chen, Junhan Yang, Mengting Liu, Xieping Huang, Ganglin Xu, Rui Xia Hao · 2024 · Diagnostic Pathology
98. Canine mammary carcinoma: current therapeutic targets and future perspectives – a review
    Muhammad Luqman Nordin, Ahmad Khusairi Azemi, Noraznawati Ismail, Abu Hassan Nordin, Walid Nabgan, Nur Amalina Noralidin, Rumaizi Shaari, Nur Zul Izzati Mohd Rajdi, Mohd Farhan Hanif Reduan, Hawa Nordin Siti et al. · 2023 · Annals of Animal Science
99. Perspectives for immunotherapy of EBV ‐associated GLELC : A relatively “hot” tumor microenvironment
    Yanna Lei, Peng Cao, Xiufeng Zheng, Jing Wei, Mo Cheng, Ming Liu · 2023 · Cancer Medicine
100. The tumor microenvironment’s in pancreatic cancer: Effects on immunotherapy success and novel strategies to overcome the hostile environment
     Jan Sören Eichhorn, Jim Petrik · 2024 · Pathology - Research and Practice